ADDED
false --12-31 FY 2025 true true true false Our board of directors is responsible for the oversight of cybersecurity risk management.
The board of directors delegates oversight of the cybersecurity risk management program to the audit committee of the board of directors (the Audit Committee ).
The Audit Committee updates the board of directors on our cybersecurity risk management program, including any critical cybersecurity risks, ongoing cybersecurity initiatives and strategies, and applicable regulatory requirements and industry standards on an annual and as-needed basis.
Our board of directors is responsible for the oversight of cybersecurity risk management.
The board of directors delegates oversight of the cybersecurity risk management program to the audit committee of the board of directors (the Audit Committee ).
The Audit Committee updates the board of directors on our cybersecurity risk management program, including any critical cybersecurity risks, ongoing cybersecurity initiatives and strategies, and applicable regulatory requirements and industry standards on an annual and as-needed basis.
Our board of directors is responsible for the oversight of cybersecurity risk management.
The board of directors delegates oversight of the cybersecurity risk management program to the audit committee of the board of directors (the Audit Committee ).
The Audit Committee updates the board of directors on our cybersecurity risk management program, including any critical cybersecurity risks, ongoing cybersecurity initiatives and strategies, and applicable regulatory requirements and industry standards on an annual and as-needed basis.
Our board of directors is responsible for the oversight of cybersecurity risk management.
REMOVED
false --12-31 FY 2024 false true true true false false false false 0.001 0.001 10,000,000 10,000,000 0 0 0 0 0.001 0.001 200,000,000 200,000,000 10,860,655 10,860,655 1,485,902 1,485,902 3 5 0 0 5 5 5 0 10.05 37.99 9.85 37.10 5 5 5 10 0 121.11 123.19 121.67 121.11 123.41 124.73 3 1 Inclusive of $3.3 million and $5.4 million of stock-based compensation expense for the years ended December 31, 2024 and 2023, respectively, and $6,693 and $15,004 of depreciation and amortization expense for the years ended December 31, 2024 and 2023, respectively.
As of March 28, 2025, there were 24,152,848 shares of the registrant s common stock outstanding.
For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future management and organizational structure and statements about our current or future product candidates and their development, our beliefs regarding their preclinical or clinical profile or efficacy, and the regulatory approval process and pathway and the timing thereof, are all forward-looking statements.
MD Anderson is currently analyzing biomarkers that would indicate lack of response in lung cancer that could enrich our population of responders in our clinical trials and enhance patient screening and enrollment in order to increase the likelihood of potential success of the Acclaim studies for the Company.
Based on a review of safety data which showed no dose limiting toxicities ( DLTs ), the Acclaim-1 SRC determined the recommended Phase 2 dose ( RP2D ) of REQORSA to be 0.12 mg/kg.
A second patient had stable disease without disease progression through 32 courses of treatment (approximately 24 months) but recently had disease progression and is no longer receiving treatment.
However, noting that both of the patients with prolonged PFS in the Phase 1 portion of the study had previously received both chemotherapy and Tagrisso, in February 2025, we amended the protocol to allow entry of patients progressing on Tagrisso or Tagrisso-containing regimens.
We expect to complete the enrollment of the first 19 patients for interim analysis in the Phase 2a expansion portion of the study by the end of 2025 and expect the interim analysis in the first half of 2026.
On December 16, 2024, we announced that we had completed the Phase 1 dose escalation portion of the Acclaim-3 clinical trial.
We anticipate that the Phase 2 expansion portion will enroll approximately 50 patients at approximately 10 to 15 U.S sites.